ARIKAYCE external R&D expenses — R&D
Insmed ARIKAYCE external R&D expenses — R&D decreased by 5.3% to $8.62M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 28.9%, from $12.12M to $8.62M. Over 3 years (FY 2022 to FY 2025), ARIKAYCE external R&D expenses — R&D shows a downward trend with a -12.1% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
Higher expenses may signal active clinical trials for new indications or label expansions, whereas lower expenses typically reflect a more mature, stable product lifecycle.
Detailed definition
This metric captures the external research and development costs directly attributable to a specific commercialized prod...
Peer comparison
Comparable to product-specific R&D spend metrics reported by other specialty pharma companies managing mature or expanding therapeutic assets.
insm_segment_arikayce_external_r_d_expenses_research_and_developmentHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $15.26M | $15.26M | $15.26M | $15.26M | $15.60M | $15.60M | $15.60M | $15.60M | $13.93M | $14.90M | $16.37M | $15.08M | $12.12M | $11.00M | $9.21M | $9.10M | $8.62M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +2.3% | +0.0% | +0.0% | +0.0% | -10.8% | +7.0% | +9.9% | -7.9% | -19.6% | -9.2% | -16.3% | -1.2% | -5.3% |
| YoY Change | — | — | — | — | +2.3% | +2.3% | +2.3% | +2.3% | -10.8% | -4.5% | +4.9% | -3.4% | -13.0% | -26.1% | -43.7% | -39.6% | -28.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Insmed's arikayce external r&d expenses — r&d?
- Insmed (INSM) reported arikayce external r&d expenses — r&d of $8.62M in Q1 2026.
- How has Insmed's arikayce external r&d expenses — r&d changed year-over-year?
- Insmed's arikayce external r&d expenses — r&d decreased by 28.9% year-over-year, from $12.12M to $8.62M.
- What is the long-term trend for Insmed's arikayce external r&d expenses — r&d?
- Over 3 years (2022 to 2025), Insmed's arikayce external r&d expenses — r&d has grown at a -12.1% compound annual growth rate (CAGR), from $61.02M to $41.44M.
- What does arikayce external r&d expenses — r&d mean?
- The total external costs incurred for research and development activities dedicated to a specific product.